- Home
- IMA vs KPTI Comparison
IMA vs KPTI Comparison
Compare IMA & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMA
- KPTI
- Stock Information
- Founded
- IMA 2019
- KPTI 2008
- Country
- IMA United States
- KPTI United States
- Employees
- IMA N/A
- KPTI N/A
- Industry
- IMA Biotechnology: Biological Products (No Diagnostic Substances)
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- IMA Health Care
- KPTI Health Care
- Exchange
- IMA Nasdaq
- KPTI Nasdaq
- Market Cap
- IMA 92.2M
- KPTI 102.4M
- IPO Year
- IMA N/A
- KPTI 2013
- Fundamental
- Price
- IMA $8.11
- KPTI $6.29
- Analyst Decision
- IMA Buy
- KPTI Strong Buy
- Analyst Count
- IMA 1
- KPTI 7
- Target Price
- IMA $30.00
- KPTI $31.71
- AVG Volume (30 Days)
- IMA 91.8K
- KPTI 302.2K
- Earning Date
- IMA 11-15-2025
- KPTI 11-11-2025
- Dividend Yield
- IMA N/A
- KPTI N/A
- EPS Growth
- IMA N/A
- KPTI N/A
- EPS
- IMA N/A
- KPTI N/A
- Revenue
- IMA $4,300,000.00
- KPTI $137,269,000.00
- Revenue This Year
- IMA N/A
- KPTI $3.40
- Revenue Next Year
- IMA N/A
- KPTI $9.69
- P/E Ratio
- IMA N/A
- KPTI N/A
- Revenue Growth
- IMA N/A
- KPTI N/A
- 52 Week Low
- IMA $7.24
- KPTI $3.51
- 52 Week High
- IMA $23.28
- KPTI $16.95
- Technical
- Relative Strength Index (RSI)
- IMA N/A
- KPTI 53.09
- Support Level
- IMA N/A
- KPTI $5.71
- Resistance Level
- IMA N/A
- KPTI $6.75
- Average True Range (ATR)
- IMA 0.00
- KPTI 0.58
- MACD
- IMA 0.00
- KPTI 0.03
- Stochastic Oscillator
- IMA 0.00
- KPTI 81.25
About IMA ImageneBio Inc. Common Stock
ImageneBio Inc is a clinical-stage biopharmaceutical company that develops differentiated therapies for immunological and inflammatory (I&I) diseases. The company is focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.